Summary

The FDA’s July 2026 action applies only to butylated hydroxytoluene (BHT), not to azodicarbonamide (ADA). The agency reopened the BHT comment period through August 31, 2026, while the ADA period remained closed after July 13. Neither reassessment immediately prohibits the additives or changes their existing U.S. authorizations. The immediate supplier task is narrower: connect actual food or food-contact uses, typical and maximum use levels, migration or decomposition evidence, safety studies, and current commercial-product identity. The most common mistake is relying on a specification, COA, or general compliance statement without showing that the submitted data represent the same grade, concentration basis, application, and processing conditions now being reviewed.

The News in Brief

The FDA added BHT and ADA to its post-market chemical review program in August 2025. On May 12, 2026, the agency formally announced reassessments of both substances under its finalized post-market assessment process. Separate requests for information were published on May 13, with an original comment deadline of July 13.

On July 29, the FDA reopened only the BHT comment period. The new deadline is August 31, 2026. The ADA comment period was not reopened because the agency had not received a request for additional time.

The FDA announcement reopening the BHT comment period does not report a final scientific assessment or any immediate change to the authorized conditions of use for BHT or ADA.

Regulatory Timeline

The FDA has not announced when either reassessment will be completed.

What Has Not Changed

The reassessments do not automatically prohibit BHT or ADA.

The BHT reopening does not reopen the ADA comment period. It also does not indicate that the FDA has reached a negative safety conclusion.

Existing U.S. authorizations remain in place unless and until the FDA completes its assessment and takes a separate risk-management or regulatory action. The U.S. review also does not automatically change the status of either substance in the European Union, Asia, or another market.

Companies should therefore avoid two opposite responses:

• Starting an immediate reformulation solely because a reassessment exists;
• Taking no action because the current authorization has not yet changed.

The appropriate response is to determine whether actual use and exposure evidence can be traced to the current commercial material.

Which Data Matter Most?

The BHT and ADA requests cover several common evidence areas. ADA requires additional attention to substances formed during processing or use.

The official BHT Request for Information asks for information including current food and food-contact uses, typical and maximum use levels, migration, market information, biomonitoring, exposure, and available safety data.

The ADA request covers similar evidence categories and also asks for actual or expected residual levels of semicarbazide, ethyl carbamate, and other decomposition products.

Four Data Errors That Can Weaken a Submission

A Legal Maximum Is Not an Actual Use Level

A regulatory maximum defines an authorized boundary. It does not show how much additive is normally used or how widely it appears within a food category.

A statement such as “used within FDA limits” does not establish:

• Typical commercial use;
• Maximum current commercial use;
• The applicable food category;
• Market penetration within that category;
• Whether the value refers to active additive or total preparation weight.

A legal maximum, a specification limit, and a typical use level answer different questions. Combining them into one number can distort exposure calculations.

Commercial-Product Weight May Not Equal Active-Additive Weight

BHT and ADA may be supplied as defined substances or as preparations containing carriers, diluents, anticaking agents, or other components.

Each reported use level should identify:

• Product code and commercial grade;
• Active-content or assay basis;
• Additive concentration in the preparation;
• As-is, dry-basis, or active-component reporting;
• Any conversion used to calculate the final level.

Two users may report the same preparation dosage while introducing different quantities of active additive.

Migration Evidence Is Application-Specific

Food-contact migration data cannot be separated from the article and conditions under which testing was performed.

Relevant records should identify:

• Contact material or article;
• Additive concentration;
• Food type or simulant;
• Temperature and contact time;
• Test construction and relevant processing conditions.

A result from one polymer, coating, gasket, adhesive, or paper system should not automatically be applied to another.

ADA Addition Level Does Not Establish Final Residue

For ADA, the quantity initially added does not by itself establish the amount of ADA or its decomposition products remaining after processing.

Residual semicarbazide, ethyl carbamate, or other products may depend on formulation, temperature, moisture, processing time, sampling point, and analytical timing.

Addition level and measured residual level should therefore be reported as different data points.

Five Checks Before the BHT Deadline

1. Connect Each Grade to an Actual Use

Map every relevant BHT or ADA product code to its:

• Commercial form;
• Active-content basis;
• Intended U.S. use;
• Food or food-contact category;
• Applicable regulatory pathway.

A substance name without its use context cannot support a meaningful exposure assessment.

2. Separate Typical, Maximum, and Legal Values

For each application, distinguish:

• Typical current use;
• Maximum current commercial use;
• Legal or specification maximum.

The calculation basis should be stated beside every value.

3. Identify Where the Evidence Is Held

Actual food-category use data are often held by food manufacturers rather than the additive producer. Food-contact migration data may be held by the packaging article producer, converter, or migration-testing laboratory. ADA decomposition data may be controlled by a customer or contract laboratory.

The task is not to request the same generic documents from every company. It is to identify which organization can provide each application-specific dataset.

4. Confirm That Studies Represent the Supplied Grade

The FDA requests do not require every company to recreate a complete new-authorization manufacturing dossier. Existing studies still need a clear connection to the current material.

For important safety, migration, or decomposition evidence, verify:

• Tested grade or formulation;
• Batch or production period;
• Specification version;
• Active-content basis;
• Relevant manufacturing or formulation changes.

Historical evidence may remain useful, but its applicability should be explained rather than assumed.

5. Record Missing Evidence as a Defined Gap

Statements such as “FDA compliant,” “food grade,” or “used within legal limits” cannot replace unavailable use, migration, decomposition, or safety data.

Each gap should be classified as:

• Data not generated;
• Data held by another organization;
• Historical evidence requiring comparability review;
• Confidential information requiring controlled access;
• Information not relevant to the intended use.

This produces a clearer evidence map than a large file package with uncertain relevance.

For buyers working across jurisdictions, the FDA review should also be separated from the authorization-application requirements discussed in the analysis of EFSA 2026 food additive application data. The two procedures may request some similar information, but they serve different regulatory decisions.

The Main Risk Is a Broken Evidence Chain

Discussion around BHT and ADA may focus on whether future restrictions will follow. The available FDA notices do not yet support that conclusion.

The more immediate weakness is often not missing documents. It is the inability to demonstrate that separate documents describe the same material and use.

A company may hold specifications, COAs, safety studies, migration reports, and sales data while still being unable to show that:

• Use levels share the same concentration basis;
• The tested substance matches the commercial preparation;
• Migration conditions represent the current article;
• ADA decomposition data match the intended process;
• Safety studies cover the supplied grade;
• Volume information corresponds to the relevant food category.

Document count is therefore a poor measure of regulatory readiness. A stronger test is whether material identity, use level, processing conditions, exposure assumptions, and safety evidence form one traceable chain.

For R&D teams, this means defining representative use and processing conditions. Quality teams need to assess comparability rather than checking only whether a report exists. Procurement teams should establish data access and change-notification expectations before approving routine commercial supply.

Short-Term and Mid-Term Implications

The existence of a reassessment alone does not justify changing materials. A gap becomes decision-relevant when the current use cannot be quantified, the evidence does not represent the commercial grade, or required migration or decomposition information cannot be linked to the intended application.

What to Watch Next

The next confirmed milestone is the August 31, 2026, BHT submission deadline.

Companies should monitor:

• Changes to the FDA review stage;
• Any preliminary scientific assessment;
• Requests focused on particular uses or exposure groups;
• Later proposals affecting authorized conditions of use.

ADA companies should continue organizing internal evidence even though the public comment period is closed. The same information may be needed for later FDA questions, customer qualification, or alternative-material evaluation.

For BHT and related antioxidant inquiries, buyers can review the available food antioxidant category and provide the commercial grade, intended U.S. use, typical use level, food or food-contact system, required migration or safety documents, quantity, and sample needs. ChemicalCell can use this information to review the relevant specification and documentation scope without treating the FDA reassessment as an immediate prohibition.